Press Releases | Health Wire East Timor

EV EDUCATION LAUNCHED IN TOP VOCATIONAL INSTITUTIONS IN SAMOA, ALONG WITH NEW DECARBONIZATION PLANS

Government of Samoa · April 8, 2025

[PRESS RELEASE 08 April 2025] – A significant educational milestone has been reached, with the opening of electric vehicles (EV) automotive workshops in three vocational institutions in Samoa, namely the National University of Samoa, Don Bosco...

Ministry of Education takes part in the III International Seminar on School Feeding in the CPLP and High Level Conference

Government of Timor-Leste · December 9, 2024

Mon. 09 of December of 2024, 11:56h The Ministry of Education of Timor-Leste, represented by Minister Dulce de Jesus Soares, accompanied by the respective delegation, took part in the III International Seminar on Good Practices in School Feeding...

Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B

GlobeNewswire, Inc. · July 15, 2019

Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa., July 15, 2019 (GLOBE NEWSWIRE) --...

Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

GlobeNewswire, Inc. · January 7, 2025

BOSTON and TEL-AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Quris-AI, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced that Merck KGaA, Darmstadt, Germany, a leading science and technology company,...

Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy

GlobeNewswire, Inc. · February 18, 2016

SAN DIEGO, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to announce that the Company’s portfolio investment company, Kannalife Sciences, Inc. (“Kannalife”), has made a major breakthrough in the field for...

K92 Mining Announces Appointment of Robert Smillie as Vice President - Exploration

GlobeNewswire, Inc. · March 20, 2025

VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQB: KNTNF) is pleased to announce the appointment of Robert Smillie, as Vice President - Exploration. The Company also announces...

Letter of Support (LOS)

U.S. Food and Drug Administration · August 28, 2024

Critical Path Institute Alpha-synuclein seeding amplification assay For the application of binary assessment of α-syn SAA as an enrichment biomarker for patient selection in clinical trials investigating therapies that are intended to treat,...

South Australian doctors head to Vanuatu in response to devastating earthquake

Premier of South Australia · December 24, 2024

Release date: 22/12/24 Three SA Health staff will travel to Vanuatu as part of the Federal Government’s response to the tragic natural disaster that occurred in the country last week. Dr James Doube, a doctor based on Kangaroo Island, will head up...

Drug Trials Snapshots: VEOZAH

U.S. Food and Drug Administration · August 23, 2024

HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic...

G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire, Inc. · June 2, 2018

RESEARCH TRIANGLE PARK, N.C., June 02, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 in combination with...

De-risking drug discovery with predictive AI

Broad Institute of MIT and Harvard · July 17, 2024

Developing a new drug can take years of research and cost millions of dollars. Still, more than 90 percent of drug candidates fail in clinical trials, with even more that never make it to the clinical stage. Many drugs fail because they simply...

U.S., Vietnamese Service Members Share Humanitarian Aid, Medical Knowledge

U.S. Department of Defense · September 12, 2017

By Air Force 1st Lt. Kellie Rizer Pacific Air Forces TAM KY, Vietnam, Sept. 12, 2017 — American and Vietnamese military members, along with several nongovernmental organizations, recently came together in Vietnam to attend seminars lead by subject...

Commitment to the Future: Progress and Continuity for the Second Year of the 9th Government

Government of Timor-Leste · August 26, 2024

Spokesperson of the Government of Timor-Leste Ninth Constitutional Government ............................................................................................................................. Press Release August 26th, 2024 Commitment...

InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing

Marketwire · March 27, 2017

SCHLIEREN, SWITZERLAND--(Marketwired - March 27, 2017) - InSphero 3D InSight™ Human Liver Microtissues were identified as a more sensitive, highly specific in vitro model for predicting drug induced liver injury (DILI) and investigating mechanisms...

January - March 2019 | Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS)

U.S. Food and Drug Administration · September 16, 2024

Product Name: Trade (Active Ingredient) or Product Class Potential Signal of a Serious Risk / New Safety Information Additional Information (as of August 5, 2024) Afinitor (everolimus) Afinitor Disperz (everolimus) Nexavar (sorafenib tosylate)...

Cooling Herbs to Beat Summer Heat

College of Naturopathic Medicine · July 4, 2024

Country(Required)Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin...

10 Ways Castor Oil Heals

College of Naturopathic Medicine · June 28, 2024

Country(Required)Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin...

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

GlobeNewswire, Inc. · December 8, 2024

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not...

The Silent Killer Chemical

College of Naturopathic Medicine · June 17, 2024

Country(Required)Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin...

Indo-Asia-Pacific Partners Discuss Global Health Interoperability at Exchange Event

U.S. Department of Defense · August 2, 2016

By Air Force Master Sgt. Todd Kabalan Defense Media Activity - Hawaii KUANTAN, Malaysia, Aug. 2, 2016 — Nearly 500 senior military health officials from 27 countries have come together for the 2016 Asia Pacific Military Health Exchange to share...